-+ 0.00%
-+ 0.00%
-+ 0.00%
Berenberg Updates Price Target, Estimates for Bayer on Pharmaceuticals Momentum
Share
Listen to the news
03:05 AM EST, 11/18/2026 (MT Newswires) -- Berenberg revised its earnings estimates and price target for Bayer (BAYN.F), citing sustained earnings momentum in the German life science company's pharmaceuticals business. "Bayer has made much of its own luck over the last year with good results in pharma and victories in front of the US Supreme Court and new bellwether Aretino glyphosate case. The success of Nubeqa and Kerendia means investors are likely right in pricing upgrades to consensus EPS, primarily driven by pharma; we believe this segment can reach over EUR5bn EBITDA in 2027 compared to the EUR4.8bn in consensus," according to a Wednesday note. The research firm believes improving performance for Bayer could pave the way for a potential initial public offering of its Monsanto unit by the late 2020s to fund its post-2030 pharma pipeline. Historically, analysts noted that management avoided discussing a split due to supervisory board concerns that a pharma-only company would be exposed to takeover risks. "From a practical standpoint, spinning out Monsanto would also be challenging without some finality on legal liabilities. Better results in pharma and the likely conclusion of settlement process in the next few months could allay these concerns," Berenberg wrote. Against this backdrop, analysts raised the hold-rated stock's price target to 62 euros from 53.50 euros. Berenberg also upgraded its EPS projections across full-year 2026 through 2028 and lifted revenue forecasts for 2027 and 2028, while slightly trimming its sales estimate for 2026.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending